t(15;17), or acute promyelocytic leukemia (APL), is a subset of acute myeloid leukemia (AML) with M3 cytomorphology, posing a potentially very dangerous subtype with high mortality due to severe coagulation abnormalities. Timely and efficient treatment can transform APL from a highly dangerous and potentially fatal state to a highly treatable leukemia.
Depending on the breakpoint in the PML gene, it may have PML::RARA transcriptional subtypes, including three isoforms, bcr1 (PML::RARA L or Long) /bcr2 (PML::RARA V or Variant ) /bcr3 (PML::RARA S or short), which respectively account for 55-50%, 10-5%, and 40-30% of cases. This one-step qualitative rRT-PCR assay developed by Amir Payvand company can specifically detect all three fusion types, directly from 500-100 nanograms of RNA, reducing the risk of contamination and error without requiring multi-step procedures.